Michael Millward - Concepedia

Author

Michael Millward

The University of Western Australia

Also Known As

M J Millward, M. J. MILLWARD, M. J. Millward, M. Millward, M.J. Millward, Michael J. Millward, Michael Millward

Publications

6.9K

Citations

H-Index

Concepts

All Affiliations

The University of Western Australia Sir Charles Gairdner Hospital Peter MacCallum Cancer Centre Russian Cancer Research Center NN Blokhin Istituto Oncologico Veneto

About

Michael Millward is an author at The University of Western Australia specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	25	4.4K
2	Health Sciences	9	9	575
3	Cell Biology	3	3	112
4	Natural Sciences	1	1	12
5	Biochemistry	1	1	12

Michael Millward

Publications

6.8K

Citations

H-Index

Page 1

	Year	Citations
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Axel Hauschild, Jean‐Jacques Grob, Lev Demidov, The Lancet OncologyBraf-mutated Metastatic MelanomaMelanomaPathologyImmune Checkpoint Inhibitor	2012	2.9K
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group Frank V. Fossella, Jose R. Pereira, Joachim von Pawel, Journal of Clinical Oncology	2003	942
Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group Agop Y. Bedikian, Michael Millward, Hubert Pehamberger, Journal of Clinical Oncology	2006	596
Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Anthony T.�C. Chan, Mow-Ming Hsu, Boon Cher Goh, Journal of Clinical Oncology	2005	289
Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel Jeremy Shapiro, Michael Millward, Danny Rischin, Gynecologic Oncology Advanced Ovarian CancerMedicineResponses SeenPharmacologyGynecology	1996	256
BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i> -Mutant Thyroid Cancer Gerald S. Falchook, Michael Millward, David S. Hong, Thyroid	2014	226
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans Roslyn J. Francis, Michael Byrne, A. A. van der Schaaf, Journal of Nuclear Medicine	2007	196
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial Peter Ellis, Frances A. Shepherd, Michael Millward, The Lancet Oncology Pretreated PatientsOncologyNcic Ctg Br.26Clinical TrialsImmune Checkpoint Inhibitor	2014	125
An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). Axel Hauschild, Jean‐Jacques Grob, Lev Demidov, Journal of Clinical Oncology PathologyPharmacotherapyOncologyMetronomic TherapyClinical Trials	2013	111
Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR Anna Reid, James Freeman, Michael Millward, Clinical Biochemistry Tumor BiologyOncologySkin CancerCancer DetectionMedicine	2014	104

Page 1